NUVB
Nuvation Bio Inc. Health Care Pharmaceutical Preparations Russell 3000
$4.76Close
$1.6BMarket cap
$4.05 – $9.5452-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 24 · weaker than 76% of stocks over 12 months
- Far from its high 50% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
50%
1wk
up 4.2%
price change
1mo
down 15.0%
price change
12-month return
down 8%
market up 11% ·
its own down 20%
F-score
—
— Not assessed
Altman Z
0.71
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.4×
price / book
Earnings yield
down 13.9%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
up 699%
year on year
EPS growth
—
latest quarter
Sales growth
up 556%
latest quarter · -2043 pts
ROE
down 53%
return on equity
Free cash margin
down 276%
-$173.4M FCF
D/E
0.15
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.3%
$0.25 a day · 2×ATR $4.26
RS
24 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- 50-day average above the 150 and 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.6% over the year, from 338m to 347m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+3% vs market2 sessions after results
Financials
- Net -325%
- Free cash -276%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $7.9M | $62.9M |
| Gross margin | — | — | — | — | 10% | — |
| Operating income | -$43.6M | -$93.3M | -$119.7M | -$99.8M | -$592.6M | -$213.1M |
| Net income | -$41.7M | -$86.8M | -$104.2M | -$75.8M | -$567.9M | -$204.6M |
| Net margin | — | — | — | — | -7214% | -325% |
| Earnings per share | — | -$438.88 | -$480.80 | -$346.32 | -$2,113.09 | -$599.13 |
| Free cash flow | -$36.5M | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
| Free cash margin | — | — | — | — | -1656% | -276% |
| Cash | $29.8M | $132.4M | $101.1M | $42.6M | $35.7M | $164.1M |
| Long-term debt | — | — | — | — | — | $47.2M |
| Shareholders' equity | $215.1M | $746.0M | $655.1M | $605.1M | $463.8M | $305.7M |
| Shares outstanding | 149.04m | 217.95m | 218.63m | 219.05m | 337.84m | 346.50m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 6, 2026 | New obligation · Other events ↗ |
| Jun 30, 2026 | Material agreement · Agreement ended · New obligation · Other events ↗ |
| May 27, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Results ↗ |
| Mar 2, 2026 | Results ↗ |
| Jan 12, 2026 | Material agreement · Results · Regulation FD ↗ |
| Nov 26, 2025 | Regulation FD · Other events ↗ |
| Nov 17, 2025 | Regulation FD · Other events ↗ |
| Nov 3, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 11, 2025 | Regulation FD · Other events ↗ |